Call Text Chat Email Refer a Patient Join a Study

Search

MotherToBaby

Medications and More during pregnancy and breastfeeding

Guanfacine (Intuniv®, Tenex®)

Selected References:

  • Apotex Corporation. Guanfacine extended release. Product label. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1c492e87-3406-ddb8-aaf2-e609c2ded503. Accessed 15 July 2025. 
  • Kittel-Schneider S, et al. 2021. Parental ADHD in pregnancy and the postpartum period –A systematic review. Neuroscience and Biobehavioral Rev 124;63-77.  
  • Lee YR, et al. 2025. Guanfacine Use in the ICU for Management of Sedation Weaning. Clin Drug Investig. 45(4):169-173. 
  • Ornoy A. 2018. Pharmacological treatment of attention deficit hyperactivity disorder during pregnancy and lactation. Pharm Res 35(3):46.  
  • Ornoy A, et al. 2021. The Effects of Drugs used for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) on Pregnancy Outcome and Breast-feeding: A Critical Review. Curr Neuropharmacol. 19(11):1794-1804. 
  • Philipp E. 1980. Guanfacine in the treatment of hypertension due to pre-eclamptic toxaemia in thirty women. Br J clin Pharmac 10: 137S-140S.  
  • Scoten O, et al. 2024. Attention-deficit/hyperactivity disorder in pregnancy and the postpartum period. Am J Obstet Gynecol. 231(1):19-35.  
  • Srinivas C, et al. 2025. Attention-Deficit/Hyperactivity Disorder Medication Use in Pregnancy and Risk of Preterm Birth: A Population-Based Cohort Study. Paediatr Perinat Epidemiol. May 14. doi: 10.1111/ppe.70031. Online ahead of print. 

 

 

 

 

 

 

 

 

 

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.